Company Overview
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +48.45% |
| 6 Months: | -14.95% |
| 3 Months: | +21.63% |
| 1 Month: | +5.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 48.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMRX Immuneering Corporation PHARMA | 4.78 | -5.14 | $309.25M | 0.00% | -26.76% | -52.15% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 480.83K | 682.57K | 748.20K | 660.04K | 482.13K | 183.70K | 94.42K | 38.38K | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
| Gross Profit | - | 243.77K | 367.57K | 339.04K | 341.44K | 263.04K | 92.85K | 46.49K | 19.04K | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
| Operating Income | - | -3.61M | -4.40M | -6.24M | -7.99M | -8.54M | -12.93M | -11.65M | -13.19M | -14.68M | -13.50M | -13.93M | -15.33M | -14.91M | -15.27M | -15.48M | -14.76M | -15.38M | -15.34M | -19.00M |
| Net Income | -3.20M | -3.60M | -4.40M | -6.23M | -7.99M | -8.53M | -12.90M | -11.53M | -12.84M | -13.60M | -12.19M | -12.60M | -14.31M | -14.08M | -14.60M | -15.05M | -14.43M | -14.96M | -13.46M | -17.27M |
| Diluted EPS | - | -0.73 | -0.89 | -1.26 | -1.61 | -0.47 | -0.49 | -0.44 | -0.49 | -0.51 | -0.43 | -0.43 | -0.49 | -0.47 | -0.49 | -0.42 | -0.40 | -0.38 | -0.21 | -0.27 |
| R&D Expense | - | 3.22M | 4.07M | 5.39M | 6.99M | 6.21M | 9.06M | 7.98M | 9.36M | 10.21M | 9.45M | 10.05M | 11.20M | 10.65M | 11.25M | 11.47M | 10.45M | 10.87M | 10.65M | 14.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.31M | 2.08M | 316.95K | 0 | - | - |
| Gross Profit | 1.03M | 926.89K | 158.83K | 0 | - | - |
| Operating Income | -17.08M | -33.89M | -51.74M | -58.41M | -64.07M | -59.38M |
| Net Income | -17.04M | -33.54M | -50.51M | -53.47M | -61.04M | -56.02M |
| Diluted EPS | -3.44 | -2.46 | -1.91 | -1.88 | -2.04 | -1.27 |
| R&D Expense | 15.00M | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 38.42M | 166.70M | 122.37M | 102.58M | 52.71M | 231.99M |
| Total Equity | -6.53M | -22.48M | 155.98M | 109.85M | 90.58M | 41.39M | 218.48M |
| Cash & Equivalents | - | 37.09M | 74.89M | 72.64M | 59.41M | 36.14M | 128.65M |
| Total Liabilities | - | 2.80M | 10.72M | 12.52M | 12.01M | 11.33M | 13.50M |
| Current Liabilities | - | 2.26M | 5.63M | 8.05M | 7.85M | 7.50M | 10.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.62M | -30.85M | -44.10M | -48.97M | -55.00M | -45.34M |
| Investing Cash Flow | -53.41K | -75.62M | 41.83M | 7.30M | 26.43M | -88.74M |
| Financing Cash Flow | 37.98M | 144.26M | 19.00K | 28.44M | 5.30M | 226.58M |
| Capital Expenditure | -53.41K | -60.79K | -742.48K | -342.75K | -84.88K | -142.23K |
| Free Cash Flow | -14.67M | -30.91M | -44.84M | -49.31M | -55.08M | -45.49M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 44.6% | 44.6% | 50.1% | - | - | - |
| Operating Margin % | -739.0% | -1,629.2% | -16,325.8% | - | - | - |
| Net Margin % | -737.2% | -1,612.3% | -15,937.3% | - | - | - |
| ROE % | 75.8% | -21.5% | -46.0% | -59.0% | -147.5% | -25.6% |
| ROCE % | -47.2% | -21.0% | -45.3% | -61.7% | -141.7% | -26.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 15.00% | 9.70M | $43.48M |
| 2 | Blackrock Inc. | 6.76% | 4.37M | $19.60M |
| 3 | Sanofi | 4.19% | 2.71M | $12.13M |
| 4 | Vanguard Capital Management LLC | 3.53% | 2.29M | $10.24M |
| 5 | Price (T.Rowe) Associates Inc | 2.99% | 1.94M | $8.67M |
| 6 | Geode Capital Management, LLC | 2.12% | 1.37M | $6.14M |
| 7 | State Street Corporation | 1.55% | 1.00M | $4.49M |
| 8 | DCF Advisers, LLC | 1.22% | 790.00K | $3.54M |
| 9 | Marshall Wace LLP | 1.13% | 731.90K | $3.28M |
| 10 | Connor Clark & Lunn Investment Management Ltd | 0.93% | 601.25K | $2.69M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMRX
Price-Driven Insight from (IMRX) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOVzJoY1RZWF9IN2lhbFc3TUhYU3R0cVFEQS1hTmRranBGeW9PN0N0QzRsbkV3dk0xUGduM1paUmMyRE50blJqLUhiLWI4bFZkSi12ZnZfQm5OM0gwT0llN0xYMTZJc0RhMEdnczh0OEZCSldSeFpndk0xOUJpRFY2ZjZKNE5hUDZiLXVVc1…
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNb2pIWFRqc3VpYVFVNEtnUWVROVpGYy1CYVhoOFFUQk1wYkhMNXg1WmFlT2ZhV1gtMWRCS3pGWW1UMG9XcjBIekljY3U4TVMxYkFVcDZJdnVCYlRzdDRzQ2lPTzRrdEg5d2NQSmk2YnhhYkNOWTUtVV9PNVFMUXFuNDhXWHd0VmpmM1dxaW…
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNcUJRS19FRkZQU05GVWo0LXlDeFIyejdMc2lUWjlKQ2JVM1dHdXg4Mll2U1AtUDhWdjNnLUllTUFER1NKTXVhRnhqa2NfV1J3OW9vZkZaNXJCZDBVampsVDFCZkk2T2w0SjR2NG9LQ1FndFZKZ29WQUV4Z0RnZmZTYVhsN29Kc19iNGZQbm…
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQWEd0bFZJM2dFZHlCeDlBdS1DZmRNbzltTVRiclFFdEM1WEpxNHhrT292Mk5DdFB4ZjVoMXV4RU9CdjZ0SkNRQUpxX2MtbHhLcHBEMVVMTVYyNE9FSlpRMmtua0NSTTBKV2ZSdDZfSXpyTTFTMEg2ZDdXSnBmdzZ5ZGFfUTV5ck9vLUhHbl…
$IMRX stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQRDI1OU9PQnJjcHhjRDhSRlMwcUpiaHFEaEgyVU1NcG9NVS1JNWpOM2FuUXBiTnI0Tzd3ZmlBdk1xWWVLaDdibTBnUXNjY25VN0wzUjhCQmJoeXNSM2ZzdHBjQ1RfQWhTaXJYQXhOdzFzbm5MNlRKVnF0ekFzVTBzS3A2d2dBNW9RRTg2ZW…
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPeW5fMjMzSm5GQ0pJajM5a0JYM2tpNTFSQVlLUWFSaGpMM3RfOHJQdlJCblltdlk0T1ZyNWdTc2lRcTBjdzNEMWpEbHNwbWp1bnpjbC04ZkNqUmlocGZybHdfSUVlSjVUdXhwQ01nLThsQWlQUWZwb19lNS1ncW9aaVA5OUk5ZVYzU0lDaH…
IMRX — Frequently Asked Questions
What is the current share price of Immuneering Corporation (IMRX)?
As of 2026-09-19 21:16 PDT, Immuneering Corporation (IMRX) trades at $4.78 on NasdaqGM. Its 52-week range is $3.04 to $9.26.
What is the market capitalisation of IMRX?
Immuneering Corporation (IMRX) has a market capitalisation of $309.25M on NasdaqGM.
What is the P/E ratio of IMRX?
IMRX trades at a trailing price-to-earnings (P/E) ratio of -5.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.52.
What is the return on equity (ROE) of IMRX?
IMRX has a return on equity (ROE) of -52.15%. Its return on capital employed (ROCE) is -26.76%.
Is IMRX a good stock to buy?
This page provides a data-driven analysis of Immuneering Corporation (IMRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.